Effects of Topical Corticosteroids, Topical Corticosteroids Under Occlusion, and Topical Brimonidine on the Prevention of Postinflammatory Hyperpigmentation After Q-Switched 532-nm Nd:YAG Laser Treatment of Solar Lentigines

Faculty of Medicine, Srinakharinwirot University0 sites36 target enrollmentOctober 24, 2023

ConditionsPost-inflammatory hyperpigmentation in patients with solar lentigines who underwent laser treatment Postinflammatory hyperpigmentation, PIH, solar lentigines

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Post-inflammatory hyperpigmentation in patients with solar lentigines who underwent laser treatment
Sponsor: Faculty of Medicine, Srinakharinwirot University
Enrollment: 36
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Topical clobetasol, topical clobetasol under occlusion, and topical brimonidine were not found to be significantly effective in reducing the incidence of PIH and intensity of PIH after laser treatment of solar lentigines on the forearms. However, topical clobetasol and topical clobetasol under occlusion might be effective in reducing posttreatment erythema.

Registry

who.int

Start Date

October 24, 2023

End Date

December 2, 2022

Last Updated

last year

Study Type

Interventional

Sex

All

Investigators

Sponsor

Faculty of Medicine, Srinakharinwirot University

Eligibility Criteria

Inclusion Criteria

•1\. Male or female subjects above 18 years of age
•2\. Subjects who have at least 8 solar lentigines on the forearms (diagnosed clinically or dermoscopically by a dermatologist). The lesions should be located on 4 different areas of the forearms; including left upper forearm, left lower forearm, right upper forearm, and right lower forearm; and there should be at least 2 lesions in each area.
•3\. Subjects who are willing to attend the project and sign informed consent form

Exclusion Criteria

•1\. Subjects who have active inflammatory diseases or infections at the site of treatment
•2\. Subjects who have photosensitive skin conditions
•3\. Subjects with a history of hypertrophic scars or keloids
•4\. Subjects with a history of skin malignancy
•5\. Subjects who received topical retinoids, hydroquinone, chemical peeling, or other topical whitening agents at the site of treatment within a period of 1 months prior to treatment
•6\. Subjects who received oral retinoids within 6 months prior to treatment
•7\. Subjects who underwent non\-ablative laser therapy at the site of treatment within a period of 3 months prior to treatment
•8\. Subjects who underwent ablative laser therapy at the site of treatment within a period of 6 months prior to treatment
•9\. Subjects who are allergic to topical analgesics, topical corticosteroids, topical brimonidine, petrolatum jelly, or other inactive ingredients of the medication such as propylene glycol, paraffin, sorbitan sesquioleate, carbomer, methylparahydroxybenzoate, phenoxyethanol, glycerol, titanium dioxide, and sodium hydroxide
•10\. Subjects who have conditions that should avoid using topical brimonidine